LIXT vs. SNGX, BIOR, FBRX, MEIP, NRBO, VINC, INDP, LUMO, SNSE, and IBIO
Should you be buying Lixte Biotechnology stock or one of its competitors? The main competitors of Lixte Biotechnology include Soligenix (SNGX), Biora Therapeutics (BIOR), Forte Biosciences (FBRX), MEI Pharma (MEIP), NeuroBo Pharmaceuticals (NRBO), Vincerx Pharma (VINC), Indaptus Therapeutics (INDP), Lumos Pharma (LUMO), Sensei Biotherapeutics (SNSE), and iBio (IBIO). These companies are all part of the "pharmaceutical preparations" industry.
Soligenix (NASDAQ:SNGX) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends, valuation and community ranking.
Lixte Biotechnology has lower revenue, but higher earnings than Soligenix. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.
Soligenix has a beta of 1.93, suggesting that its stock price is 93% more volatile than the S&P 500. Comparatively, Lixte Biotechnology has a beta of -0.23, suggesting that its stock price is 123% less volatile than the S&P 500.
Lixte Biotechnology has a net margin of 0.00% compared to Lixte Biotechnology's net margin of -1,025.66%. Lixte Biotechnology's return on equity of -198.36% beat Soligenix's return on equity.
In the previous week, Soligenix had 3 more articles in the media than Lixte Biotechnology. MarketBeat recorded 6 mentions for Soligenix and 3 mentions for Lixte Biotechnology. Soligenix's average media sentiment score of 1.59 beat Lixte Biotechnology's score of 0.59 indicating that Lixte Biotechnology is being referred to more favorably in the news media.
Soligenix currently has a consensus price target of $3.00, suggesting a potential upside of 757.14%. Given Lixte Biotechnology's higher probable upside, equities analysts clearly believe Soligenix is more favorable than Lixte Biotechnology.
Soligenix received 278 more outperform votes than Lixte Biotechnology when rated by MarketBeat users.
3.6% of Soligenix shares are held by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are held by institutional investors. 1.4% of Soligenix shares are held by company insiders. Comparatively, 15.5% of Lixte Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Soligenix beats Lixte Biotechnology on 9 of the 14 factors compared between the two stocks.
Get Lixte Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for LIXT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LIXT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lixte Biotechnology Competitors List
Related Companies and Tools
